Status:
UNKNOWN
Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring
Lead Sponsor:
Wuhan Asia Heart Hospital
Conditions:
Myocardial Infarction
Venous Thromboembolism
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Background: Unfractionated heparin (UFH) is a sulfated polysaccharide extracted from porcine intestinal mucosa that enhances the inhibitory activity of the natural anticoagulant antithrombin towards ...
Detailed Description
Aim of the study Based on available data, a randomized trial aimed at comparing the efficacy and safety of monitoring UFH treatments using aPTT and anti-FXa activity in patients treated with fulldoses...
Eligibility Criteria
Inclusion
- acute venous thromboembolism,
- acute coronary syndrome
- receiving UFH therapy.
Exclusion
- non-willing to participate in the study,
- thrombolytic therapy,
- previous treatment with heparin (UFH) of more than one day before randomization,
- history of heparin-induced thrombocytopenia.
- other conditions considering by study clinians that are not suitable for the trail.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2018
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT03426982
Start Date
March 1 2018
End Date
October 30 2018
Last Update
March 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wuhan Asia Heart Hospital
Wuhan, Hubei, China, 430022